Update on emerging urate-lowering therapies

被引：58

作者：

Chohan, Saima ^{[1
]}

Becker, Michael A. ^{[1
]}

机构：

[1] Univ Chicago, Med Ctr, Pritzker Sch Med, Rheumatol Sect,Dept Med, Chicago, IL 60637 USA

来源：

CURRENT OPINION IN RHEUMATOLOGY | 2009年 / 21卷 / 02期

关键词：

allopurinol; benzbromarone; febuxostat; probenecid; puricase; TREATMENT-FAILURE GOUT; PEGLOTICASE PGL THERAPY; DOUBLE-BLIND; SERUM URATE; SELECTIVE INHIBITOR; NON-PURINE; URIC-ACID; ALLOPURINOL; HYPERURICEMIA; FEBUXOSTAT;

D O I：

10.1097/BOR.0b013e328325bd94

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Purpose of review To discuss currently available urate-lowering therapeutic options for gout in the United States and newer therapeutic initiatives in development. Recent findings Currently available urate-lowering drugs include allopurinol and probenecid. These drugs are effective but are often underdosed or underutilized, and caution must be taken in patients with multiple comorbidities. Newer therapeutic agents in development include febuxostat, a nonpurine analogue xanthine oxidase inhibitor, and pegloticase, a pegylated recombinant uricase. Summary There have been no new US Food and Drug Administration-approved urate-lowering drugs for gout in the past 40 years. Recent advances in therapeutics promise to provide the opportunity for much needed improvement in patient outcomes in this disorder.

引用

页码：143 / 149

页数：7

共 44 条

[1]

ALLOPURINOL HYPERSENSITIVITY SYNDROME - A REVIEW [J].

ARELLANO, F ;

SACRISTAN, JA .

ANNALS OF PHARMACOTHERAPY, 1993, 27 (03) :337-343

[2]

Arromdee E, 2002, J RHEUMATOL, V29, P2403

[3]

Baraf HS, 2008, ARTHRITIS RHEUM, V58, pS176

[4]

Becker GM, 2008, ARTHRITIS RHEUM, V58, P4029

[5]

Becker MA, 2008, ARTHRITIS RHEUM, V58, pS880

[6]

Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers [J].

Becker, MA ;

Kisicki, J ;

Khosravan, R ;

Wu, J ;

Mulford, D ;

Hunt, B ;

MacDonald, P ;

Joseph-Ridge, N .

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2004, 23 (8-9) :1111-1116

[7]

Febuxostat compared with allopurinol in patients with hyperuricemia and gout [J].

Becker, MA ;

Schumacher, HR ;

Wortmann, RL ;

MacDonald, PA ;

Eustace, D ;

Palo, WA ;

Streit, J ;

Joseph-Ridge, N .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (23) :2450-2461

[8]

BECKER MA, J RHEUMATOL IN PRESS

[9]

We can make gout management more successful now [J].

Becker, Michael A. ;

Chohan, Saima .

CURRENT OPINION IN RHEUMATOLOGY, 2008, 20 (02) :167-172

[10]

Hyperuricemia and associated diseases [J].

Becker, Michael A. ;

Jolly, Meenakshi .

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2006, 32 (02) :275-+

← 1 2 3 4 5 →